BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7035323)

  • 1. Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism.
    Mantero F; Opocher G; Boscaro M; Valpione E; Armanini D; Fallo F
    Horm Metab Res; 1981 Aug; 13(8):464-7. PubMed ID: 7035323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism.
    Mizuno K; Yamazaki M; Ikeda K; Yaginuma K; Hashimoto S; Fukuchi S
    Jpn Heart J; 1983 Nov; 24(6):917-24. PubMed ID: 6323781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pizotifen, a serotonin antagonist, and of pirenzepine, a muscarinic antagonist, on hormonal responses to metoclopramide in healthy subjects.
    Jungmann E; Althoff PH; Hermann GJ; Schöffling K
    Arzneimittelforschung; 1984; 34(9):1022-4. PubMed ID: 6391497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
    Carey RM; Thorner MO; Ortt EM
    J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of dopaminergic antagonists on plasma aldosterone in normal subjects and patients with hypopituitarism].
    Shikuma R; Yoshimura M; Takashina R; Yamazaki H; Kambara S; Ijichi H
    Nihon Naibunpi Gakkai Zasshi; 1984 Sep; 60(9):1041-5. PubMed ID: 6394371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
    Witzgall H; von Werder K; Weber PC
    J Steroid Biochem; 1983 Nov; 19(5):1671-6. PubMed ID: 6645503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-responsiveness of aldosterone to metoclopramide in aldosteronism.
    Gniadek TC; Grekin RJ; Gross MD; Villareal JZ
    Clin Endocrinol (Oxf); 1982 May; 16(5):475-81. PubMed ID: 7044619
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
    García-Robles R; Ruilope L; Mancheño E; Hurtado A; Alcázar JM; Varela C; de la Calle H; Rodicio JL; Sancho J
    Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.
    Kem DC; Weinberger MH; Gomez-Sanchez C; Kramer NJ; Lerman R; Furuyama S; Nugent CA
    J Clin Invest; 1973 Sep; 52(9):2272-7. PubMed ID: 4353776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
    Ganguly A; Pratt JH; Weinberger MH; Grim CE; Fineberg NS
    J Clin Endocrinol Metab; 1983 Aug; 57(2):388-92. PubMed ID: 6306041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of diazoxide on blood pressure, PRA and plasma aldosterone in hypertensive patients (author's transl)].
    Mantero F; Perini A; Armanini D; Gion M; Opocher G; Boscaro M
    G Ital Cardiol; 1976; 6(7):1246-53. PubMed ID: 1010235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lack of effect of aging on dopaminergic inhibition of aldosterone and prolactin increase].
    Preis P; Luger A; Templ H; Tragl HK; Geyer G
    Z Gerontol; 1985; 18(4):241-3. PubMed ID: 3901563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary peptides other than ACTH may not be aldosterone secretagogue in primary aldosteronism.
    Miyamori I; Koshida H; Matsubara T; Soma R; Takasaki H; Okamoto S; Takeda R
    Exp Clin Endocrinol; 1990 Aug; 95(3):323-9. PubMed ID: 2174003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism.
    Witzgall H; Lorenz R; von Werder K; Weber PC
    Clin Sci (Lond); 1985 Mar; 68(3):291-9. PubMed ID: 3882312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.
    Trenkel S; Seifarth C; Schobel H; Hahn EG; Hensen J
    Exp Clin Endocrinol Diabetes; 2002 Apr; 110(2):80-5. PubMed ID: 11928071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
    Jungmann E; Althoff PH; Rosak C; Schwedes U; Schöffling K
    Horm Metab Res; 1986 Feb; 18(2):138-40. PubMed ID: 3699687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of metoclopramide, a dopamine inhibitor, on aldosterone secretion in patients with primary aldosteronism].
    Mizuno K; Yaginuma K; Yamazaki M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1982 Aug; 58(8):976-83. PubMed ID: 6292008
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
    Zacharieva S; Stoeva I; Matrozov P; Andonova K
    Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of aldosterone secretion in primary aldosteronism.
    Vetter H; Vetter W
    Horm Metab Res; 1975 Sep; 7(5):418-24. PubMed ID: 1183923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.